Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Diazoxide (Primary)
- Indications Prader-Willi syndrome
- Focus Registrational; Therapeutic Use
- Acronyms DESTINY PWS
- Sponsors Soleno Therapeutics
- 14 Jan 2023 Results assessing effect of Diazoxide Choline Extended-Release Tablet in People with Prader-Willi Syndrome published in the Journal of Clinical Endocrinology and Metabolism
- 13 Jun 2022 According to a Soleno Therapeutics media release, Dr. Felner is the principal investigator of the study.
- 13 Jun 2022 Results published in the Soleno Therapeutics Media Release.